Dear Dr. Martin Hovland, We learned from the literature that premixed insulins are short-acting insulin or rapid-acting insulin analogue mixed with intermediate-acting insulin in a fixed ratio, addressing FBG and PPBG...Dear Dr. Martin Hovland, We learned from the literature that premixed insulins are short-acting insulin or rapid-acting insulin analogue mixed with intermediate-acting insulin in a fixed ratio, addressing FBG and PPBG in one injection. There are two categories;high-mix and low-mix premixed insulins. We, a Saudi task force, gathered to develop an explicit, evidence-based consensus for the use of the low-mix premixed insulin for better glycemic control. The treatment with premixed aspart 30 was non-inferior to treatment with premixed insulin lispro 25. In addition, Self-monitored blood glucose levels were comparable. Safety profiles were similar between both treatments, as was the incidence of hypoglycemic episodes. The switch between both products of the low-mix family can be carried out without any problem. Both products of the low-mix premixed insulin analogues aspart 30/70 and premixed insulin lispro 25/75 have comparable efficacy and safety as shown from the medical literature. Therefore, we can change from one to another safely as demonstrated by the US FDA statement. In addition, the ergonomic features of KwikPen’s design and function may offer important advantages for the user during insulin administration.展开更多
Objective:To analyze the level of blood glucose fluctuation and the time of blood glucose reaching the standard in the treatment of type 2 diabetes mellitus with premixed insulin regimen and three plus one intensive h...Objective:To analyze the level of blood glucose fluctuation and the time of blood glucose reaching the standard in the treatment of type 2 diabetes mellitus with premixed insulin regimen and three plus one intensive hypoglycemic regimen.Methods:A total of 120 patients with type 2 diabetes who were admitted to our hospital from April 2017 to April 2018 were divided into observation group and control group according to random number method,with 60 cases in each group.Patients in the control group were given insulin asparagus injection before breakfast and dinner,while patients in the observation group were given insulin Laipu injection before three meals combined with insulin glargine injection before bedtime.The insulin dosage,blood glucose compliance time,SDBG,CV,and quartile blood glucose fluctuation range were compared between the two groups.IQR,PPGE and other indicators of blood glucose fluctuations.Results:After treatment,the insulin dosage and blood glucose compliance time of the observation group were significantly lower than those of the control group(P<0.05).There was no significant difference in the incidence of hypoglycemia between the two groups(P>0.05).The SDBG,IQR,and PPGE of the day were significantly lower(P<0.05),and the CV was significantly higher(P<0.05).After two days of blood glucose compliance,the serum levels of SDBG,CV,IQR,and PPGE were significantly lower in the observation group than those in the control group(P<0.05).Conclusions:Compared with the premixed insulin regimen,the three plus one intensive hypoglycemic regimen has a better effect on controlling blood sugar fluctuation in type 2 diabetes mellitus,and the time for blood sugar to reach the standard is relatively short,and also the incidence of hypoglycemia is relatively low.Hence,it is worth popularizing in clinical practice.展开更多
目的分析气阴两虚型2型糖尿病(diabetes mellitus type 2,T2DM)患者采用参芪降糖颗粒与预混胰岛素联合治疗的效果。方法便利选取2022年8月—2023年7月济南市章丘区中医医院收治的102例T2DM气阴两虚型患者为研究对象,按照随机数表法分为...目的分析气阴两虚型2型糖尿病(diabetes mellitus type 2,T2DM)患者采用参芪降糖颗粒与预混胰岛素联合治疗的效果。方法便利选取2022年8月—2023年7月济南市章丘区中医医院收治的102例T2DM气阴两虚型患者为研究对象,按照随机数表法分为两组。研究组(51例)采用参芪降糖颗粒与预混胰岛素联合治疗,对照组(51例)仅采用预混胰岛素治疗。比较两组血糖指标、中医证候积分、胰岛功能与不良反应情况。结果治疗3个月后,与对照组相比,研究组餐后2 h血糖、空腹血糖、糖化血红蛋白值均更低,差异有统计学意义(P均<0.05)。研究组中医证候积分为(6.02±1.42)分,低于对照组的(8.03±1.35)分,差异有统计学意义(t=7.326,P<0.05)。与对照组相比,研究组胰岛β细胞功能指数更高,胰岛素抵抗指数更低,差异有统计学意义(P均<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论气阴两虚型T2DM患者采用预混胰岛素与参芪降糖颗粒联合治疗有效保障了血糖控制效果,缓解相关症状,改善胰岛功能,具有较高的临床应用价值。展开更多
目的探讨地特胰岛素联合瑞格列奈治疗老年2型糖尿病患者的有效性和安全性。方法选择2011年6月至2013年6月开封市第二人民医院收治的60例老年2型糖尿病患者作为研究对象,采用随机数字表法分为两组:观察组30例,使用地特胰岛素联合瑞格列...目的探讨地特胰岛素联合瑞格列奈治疗老年2型糖尿病患者的有效性和安全性。方法选择2011年6月至2013年6月开封市第二人民医院收治的60例老年2型糖尿病患者作为研究对象,采用随机数字表法分为两组:观察组30例,使用地特胰岛素联合瑞格列奈进行治疗;对照组30例,使用预混胰岛素进行治疗。观察两组患者治疗前后的空腹血糖(FBG)、糖化血红蛋白(Hb A1c)、餐后2 h血糖(2 h BG)、体质指数(BMI)、血糖波动幅度(MAGE)以及平均血糖(MBG)和血糖变异系数(CV),然后进行对比分析并对其安全性进行评价。结果治疗后两组患者的FBG、2 h BG、Hb A1c、MBG、MAGE均低于治疗前,差异有统计学意义(P<0.05),且观察组降低幅度大于对照组(P<0.05);观察组CV治疗前后比较差异有统计学意义,且观察组降低幅度大于对照组(P<0.05)。结论使用地特胰岛素联合瑞格列奈对老年2型糖尿病进行治疗,疗效确切,能够有效降低低血糖的发生频率和程度,安全性比较高。展开更多
目的以复合终点达标率为评价指标,比较利拉鲁肽与预混胰岛素治疗新诊断2型糖尿病患者的短期疗效。方法选取2012年1月-2013年5月该院新诊断2型糖尿病患者80例,按随机数字表随机分为利拉鲁肽组(n=40)和预混胰岛素组(n=40),分别给予利拉鲁...目的以复合终点达标率为评价指标,比较利拉鲁肽与预混胰岛素治疗新诊断2型糖尿病患者的短期疗效。方法选取2012年1月-2013年5月该院新诊断2型糖尿病患者80例,按随机数字表随机分为利拉鲁肽组(n=40)和预混胰岛素组(n=40),分别给予利拉鲁肽和预混胰岛素治疗,疗程12周。分别于0周及12周测收缩压(SBP)、舒张压(DBP)、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、空腹血糖(FPG)、餐后2 h血糖(2 h PBG)、糖化血红蛋白(Hb A1c),计算体重指数(BMI),记录低血糖发生情况。以Hb A1c<7.0%、血压<130/80 mm Hg、TG<1.7 mmol/L、LDL-C<2.6 mmol/L、BMI<24 kg/m2,以及没有发生低血糖事件构建复合终点达标标准。结果治疗前两组各项指标比较差异均无统计学意义(P>0.05);治疗后两组BMI、FPG、2 h PBG、Hb A1c均显著下降(P<0.01),利拉鲁肽组TC亦显著下降(P<0.05)。两组SBP、DBP、TG、LDL-C及预混胰岛素组TC的差异均无统计学意义(P>0.05);两组间BMI、SBP、DBP、TG、TC、LDL-c、FPG、2 h PBG、Hb A1c差异均无统计学意义(P>0.05)。利拉鲁肽组低血糖发生率为2.6%,显著低于预混胰岛素组(P<0.05),复合终点达标率为41%,显著高于预混胰岛素组(P<0.05)。结论以复合终点达标率为评价指标,利拉鲁肽治疗新诊断2型糖尿病患者的短期疗效显著优于预混胰岛素。展开更多
文摘Dear Dr. Martin Hovland, We learned from the literature that premixed insulins are short-acting insulin or rapid-acting insulin analogue mixed with intermediate-acting insulin in a fixed ratio, addressing FBG and PPBG in one injection. There are two categories;high-mix and low-mix premixed insulins. We, a Saudi task force, gathered to develop an explicit, evidence-based consensus for the use of the low-mix premixed insulin for better glycemic control. The treatment with premixed aspart 30 was non-inferior to treatment with premixed insulin lispro 25. In addition, Self-monitored blood glucose levels were comparable. Safety profiles were similar between both treatments, as was the incidence of hypoglycemic episodes. The switch between both products of the low-mix family can be carried out without any problem. Both products of the low-mix premixed insulin analogues aspart 30/70 and premixed insulin lispro 25/75 have comparable efficacy and safety as shown from the medical literature. Therefore, we can change from one to another safely as demonstrated by the US FDA statement. In addition, the ergonomic features of KwikPen’s design and function may offer important advantages for the user during insulin administration.
基金This study was supported the Cultivation Fund for Key Scientific Research Project of Minnan Medical College(Grant No.WK2016ZF01).
文摘Objective:To analyze the level of blood glucose fluctuation and the time of blood glucose reaching the standard in the treatment of type 2 diabetes mellitus with premixed insulin regimen and three plus one intensive hypoglycemic regimen.Methods:A total of 120 patients with type 2 diabetes who were admitted to our hospital from April 2017 to April 2018 were divided into observation group and control group according to random number method,with 60 cases in each group.Patients in the control group were given insulin asparagus injection before breakfast and dinner,while patients in the observation group were given insulin Laipu injection before three meals combined with insulin glargine injection before bedtime.The insulin dosage,blood glucose compliance time,SDBG,CV,and quartile blood glucose fluctuation range were compared between the two groups.IQR,PPGE and other indicators of blood glucose fluctuations.Results:After treatment,the insulin dosage and blood glucose compliance time of the observation group were significantly lower than those of the control group(P<0.05).There was no significant difference in the incidence of hypoglycemia between the two groups(P>0.05).The SDBG,IQR,and PPGE of the day were significantly lower(P<0.05),and the CV was significantly higher(P<0.05).After two days of blood glucose compliance,the serum levels of SDBG,CV,IQR,and PPGE were significantly lower in the observation group than those in the control group(P<0.05).Conclusions:Compared with the premixed insulin regimen,the three plus one intensive hypoglycemic regimen has a better effect on controlling blood sugar fluctuation in type 2 diabetes mellitus,and the time for blood sugar to reach the standard is relatively short,and also the incidence of hypoglycemia is relatively low.Hence,it is worth popularizing in clinical practice.
文摘目的分析气阴两虚型2型糖尿病(diabetes mellitus type 2,T2DM)患者采用参芪降糖颗粒与预混胰岛素联合治疗的效果。方法便利选取2022年8月—2023年7月济南市章丘区中医医院收治的102例T2DM气阴两虚型患者为研究对象,按照随机数表法分为两组。研究组(51例)采用参芪降糖颗粒与预混胰岛素联合治疗,对照组(51例)仅采用预混胰岛素治疗。比较两组血糖指标、中医证候积分、胰岛功能与不良反应情况。结果治疗3个月后,与对照组相比,研究组餐后2 h血糖、空腹血糖、糖化血红蛋白值均更低,差异有统计学意义(P均<0.05)。研究组中医证候积分为(6.02±1.42)分,低于对照组的(8.03±1.35)分,差异有统计学意义(t=7.326,P<0.05)。与对照组相比,研究组胰岛β细胞功能指数更高,胰岛素抵抗指数更低,差异有统计学意义(P均<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论气阴两虚型T2DM患者采用预混胰岛素与参芪降糖颗粒联合治疗有效保障了血糖控制效果,缓解相关症状,改善胰岛功能,具有较高的临床应用价值。
文摘目的探讨地特胰岛素联合瑞格列奈治疗老年2型糖尿病患者的有效性和安全性。方法选择2011年6月至2013年6月开封市第二人民医院收治的60例老年2型糖尿病患者作为研究对象,采用随机数字表法分为两组:观察组30例,使用地特胰岛素联合瑞格列奈进行治疗;对照组30例,使用预混胰岛素进行治疗。观察两组患者治疗前后的空腹血糖(FBG)、糖化血红蛋白(Hb A1c)、餐后2 h血糖(2 h BG)、体质指数(BMI)、血糖波动幅度(MAGE)以及平均血糖(MBG)和血糖变异系数(CV),然后进行对比分析并对其安全性进行评价。结果治疗后两组患者的FBG、2 h BG、Hb A1c、MBG、MAGE均低于治疗前,差异有统计学意义(P<0.05),且观察组降低幅度大于对照组(P<0.05);观察组CV治疗前后比较差异有统计学意义,且观察组降低幅度大于对照组(P<0.05)。结论使用地特胰岛素联合瑞格列奈对老年2型糖尿病进行治疗,疗效确切,能够有效降低低血糖的发生频率和程度,安全性比较高。
文摘目的以复合终点达标率为评价指标,比较利拉鲁肽与预混胰岛素治疗新诊断2型糖尿病患者的短期疗效。方法选取2012年1月-2013年5月该院新诊断2型糖尿病患者80例,按随机数字表随机分为利拉鲁肽组(n=40)和预混胰岛素组(n=40),分别给予利拉鲁肽和预混胰岛素治疗,疗程12周。分别于0周及12周测收缩压(SBP)、舒张压(DBP)、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、空腹血糖(FPG)、餐后2 h血糖(2 h PBG)、糖化血红蛋白(Hb A1c),计算体重指数(BMI),记录低血糖发生情况。以Hb A1c<7.0%、血压<130/80 mm Hg、TG<1.7 mmol/L、LDL-C<2.6 mmol/L、BMI<24 kg/m2,以及没有发生低血糖事件构建复合终点达标标准。结果治疗前两组各项指标比较差异均无统计学意义(P>0.05);治疗后两组BMI、FPG、2 h PBG、Hb A1c均显著下降(P<0.01),利拉鲁肽组TC亦显著下降(P<0.05)。两组SBP、DBP、TG、LDL-C及预混胰岛素组TC的差异均无统计学意义(P>0.05);两组间BMI、SBP、DBP、TG、TC、LDL-c、FPG、2 h PBG、Hb A1c差异均无统计学意义(P>0.05)。利拉鲁肽组低血糖发生率为2.6%,显著低于预混胰岛素组(P<0.05),复合终点达标率为41%,显著高于预混胰岛素组(P<0.05)。结论以复合终点达标率为评价指标,利拉鲁肽治疗新诊断2型糖尿病患者的短期疗效显著优于预混胰岛素。
